Video

It's an Exciting Time for Mantle Cell Lymphoma

Author(s):

Michael Wang, M.D.

There are many exciting advances happening in the field of mantle cell lymphoma.

It is an exciting time for mantle cell lymphoma (MCL), with new treatments being explored that will lead to better patient outcomes, according to Michael Wang, M.D., professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center.

Progress is being made in targeted therapies, immunotherapy and cell therapies, according to Wang, who said that in his lifetime, there might be a percentage of patients who are cured of the disease.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Related Content
Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer
March 6th 2025

Artificial Intelligence Enhances Polyp Detection in Colorectal Cancer

Ryan Scott
Artificial intelligence aids in polyp detection, enhancing colonoscopy effectiveness and reducing the risk of colorectal cancer progression in patients.
Image of Dr. Fakih.
February 27th 2025

ctDNA Alone ‘Not Sufficient’ When Monitoring Patients With Colorectal Cancer

Dr. Marwan Fakih
The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.
Image of doctor with brown hair.
February 25th 2025

Some KRAS Mutations Associated With Worse Outcomes in Pancreatic Cancer

Dr. Vaia Florou
In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, researchers have found.
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
February 21st 2025

How Patients With Cancer Can Avoid Counterfeit Therapeutics Online

Dr. Megan Menon
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
Dr. Robert Jones is a professor of Clinical Cancer Research at The University of Glasgow School of Cancer Sciences, in Scotland.
February 15th 2025

Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer

Dr. Robert Jones
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Dr. Tycel Phillips discusses the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL. | © Digilife - stock.adobe.com
February 11th 2025

FDA Approval of Calquence Combo Brings Optimism in MCL

Ryan Scott
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.